drugset
drugset / Trial / NCT05742022

"Phospholipovit" vs Placebo in Patients With Combined Hyperlipidemia

NCT05742022 ↗

Phase 2/3 Completed 100 enrolled Institute of Biomedical Chemistry, Russia
RandomizedParallel-groupDouble-blindTreatment

Summary

"Phospholipovit" vs placebo in patients with combined hyperlipidemia

Timeline

Start
2016-01-01
Primary completion
2018-06-20
Completion
2022-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Phospholipovit Other / unclassified 500 mg Oral

Indications

hyperlipidemia, combined, 2